ELAVL2: A Potential Drug Target and Biomarker (G1993)
![Review Report on ELAVL2 Target / Biomarker](https://silexon.ai/img/target-biomarker-review.jpg?a=1)
![Content of Review Report on ELAVL2 Target / Biomarker](https://silexon.ai/img/target-biomarker-review-content.jpg?a=2)
ELAVL2: A Potential Drug Target and Biomarker
ELAVL2 (endoplasmic reticulum-associated protein L2) is a protein that is expressed in various tissues and cells throughout the body. Its functions include regulating protein synthesis, localizing to the endoplasmic reticulum, and playing a role in the development and progression of various diseases, including cancer.
Despite its importance, little is known about ELAVL2 and its potential as a drug target or biomarker. In this article, we will explore the biology and potential applications of ELAVL2, with a focus on its potential as a drug target and its potential as a biomarker for various diseases.
ELAVL2 as a Drug Target
The potential of ELAVL2 as a drug target is based on its various functions, including its role in regulating protein synthesis and its association with various diseases, including cancer.
One of the key functions of ELAVL2 is its role in regulating protein synthesis. ELAVL2 has been shown to play a role in the regulation of protein synthesis by interacting with various cellular signaling pathways, including the PI3K/Akt signaling pathway. This interaction between ELAVL2 and the PI3K/Akt signaling pathway suggests that ELAVL2 may be a potential drug target for diseases that are characterized by the overproduction or dysfunction of proteins.
Another potential mechanism by which ELAVL2 may be targeted as a drug is its association with various diseases, including cancer. ELAVL2 has been shown to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, studies have shown that ELAVL2 has been involved in the development and progression of these cancers.
ELAVL2 as a Biomarker
ELAVL2 may also have potential as a biomarker for various diseases. Its association with various diseases, including cancer, suggests that it may be a useful biomarker for these diseases.
One of the key applications of ELAVL2 as a biomarker is its ability to be easily measured and detected. ELAVL2 is a protein that is expressed in various tissues and cells throughout the body, which makes it relatively easy to detect and measure. Additionally, its expression is often affected by the expression of other genes, which makes it relatively easy to study and determine if it is being altered in response to various stimuli.
ELAVL2 has been shown to be involved in the development and progression of various diseases, including cancer. Its association with these diseases suggests that it may be a useful biomarker for these conditions. Additionally, its expression has been shown to be affected by various factors, including the expression of other genes and the presence of certain substances, which makes it relatively easy to study and determine if it is being altered in response to these factors.
Conclusion
ELAVL2 is a protein that has been shown to play a role in various functions, including regulating protein synthesis and its association with various diseases, including cancer. Its potential as a drug target and biomarker is based on its interaction with various cellular signaling pathways and its association with various diseases. Further research is needed to fully understand the potential of ELAVL2 as a drug target and biomarker.
Protein Name: ELAV Like RNA Binding Protein 2
Functions: RNA-binding protein that binds to the 3' untranslated region (3'UTR) of target mRNAs (By similarity). Seems to recognize a GAAA motif (By similarity). Can bind to its own 3'UTR, the FOS 3'UTR and the ID 3'UTR (By similarity)
The "ELAVL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELAVL2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ELAVL3 | ELAVL4 | ELDR | ELF1 | ELF2 | ELF2P4 | ELF3 | ELF3-AS1 | ELF4 | ELF5 | ELFN1 | ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3 | EMSLR | EMSY | EMX1 | EMX2 | EMX2OS | EN1 | EN2 | ENAH | ENAM | ENC1 | ENDOD1 | ENDOG